Response to letter entitled : Re: Oral cavity adjuvant therapy (OCAT) - a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity
| Errataetall: |
CommentOn: Eur J Cancer. 2023 Aug;189:112918. - PMID 37321930 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 189(2023) vom: 13. Aug., Seite 112922 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghosh-Laskar, Sarbani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase III |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 05.12.2023 published: Print-Electronic CommentOn: Eur J Cancer. 2023 Aug;189:112918. - PMID 37321930 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2023.05.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358235200 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358235200 | ||
| 003 | DE-627 | ||
| 005 | 20231226074319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.05.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358235200 | ||
| 035 | |a (NLM)37321931 | ||
| 035 | |a (PII)S0959-8049(23)00246-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghosh-Laskar, Sarbani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to letter entitled |b Re: Oral cavity adjuvant therapy (OCAT) - a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 05.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Eur J Cancer. 2023 Aug;189:112918. - PMID 37321930 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 700 | 1 | |a Chatterjee, Abhishek |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Shwetabh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 189(2023) vom: 13. Aug., Seite 112922 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:189 |g year:2023 |g day:13 |g month:08 |g pages:112922 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2023.05.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 189 |j 2023 |b 13 |c 08 |h 112922 | ||